Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day)

Robert GoodnoughCalifornia Poison Control System San Francisco Division, San Francisco, CA, USA; ;Department of Emergency Medicine, University of California San Francisco, San Francisco, CA, USA; Correspondence[email protected]

http://orcid.org/0000-0001-5333-087X

Mariko NomuraDepartment of Emergency Medicine, Alameda Health System-Highland Hospital, Oakland, CA, USA;

Adina BadeaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA;

Kara L. LynchDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA;

Neal L. BenowitzDepartments of Medicine and Bioengineering & Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA

Ben TsutaokaDepartment of Emergency Medicine, University of California San Francisco, San Francisco, CA, USA;

References

Eggleston W, Marraffa JM, Stork CM, et al. Notes from the field: cardiac dysrhythmias after loperamide abuse — New York, 2008–2016. MMWR Morb Mortal Wkly Rep. 2016;65(45):1276–1277.
PubMed Web of Science ®Google Scholar
Vaz RJ, Kang J, Luo Y, et al. Molecular determinants of loperamide and N-desmethyl loperamide binding in the hERG cardiac K + channel. Bioorg Med Chem Lett. 2018;28:446–451.
PubMed Web of Science ®Google Scholar
Swank KA, Wu E, Kortepeter C, et al. Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse. J Am Pharm Assoc. 2017;57:S63–S67.
Google Scholar
Hurtado-Torres GF, Sandoval-Munro RL. An additional clinical scenario of risk for loperamide cardiac-induced toxicity. Am J Med. 2016;129:e33.
PubMed Web of Science ®Google Scholar
Enakpene EO, Riaz IB, Shirazi FM, et al. The long QT teaser: loperamide abuse. Am J Med. 2015;128:1083–1086.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day)

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day)

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date